19 September 2022 - Celltrion said that the UK's MHRA has approved Vegzelma, a biosimilar referencing Avastin (bevacizumab), to treat various cancer.

The company received full label approval for all of Avastin's indications, including metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and metastatic breast cancer.

Read Korea Biomedical Review article